Evidence map›Paper›PMID 29745356›Full record

Observational studyInfection control and hospital epidemiology2018

Noninfectious Hospital Adverse Events Decline After Elimination of Contact Precautions for MRSA and VRE.

Elise M Martin, Brandy Bryant, Tristan R Grogan, Zachary A Rubin, Dana L Russell, David Elashoff, Daniel Z Uslan

Open access · bronzeAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Infection control and hospital epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026
    Review
  3. Article
  4. Doff Thy Gown-Shedding Contact Precautions for COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  5. Article
  6. Contact precautions for MRSA and VRE: where are we now? A survey of theAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Barrier Precautions in the Era of Multidrug Pathogens.Current treatment options in infectious diseases · 2020
    Review
  13. Article
  14. Article
  15. Observational
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elise M Martin1Division of Infectious Diseases,David Geffen School of Medicine at UCLA,Los Angeles,California.
Brandy Bryant2Department of Quality Management,UCLA Health,Los Angeles,California.
Tristan R Grogan3Department of Medicine Statistics Core,David Geffen School of Medicine at UCLA,Los Angeles,California.
Zachary A Rubin1Division of Infectious Diseases,David Geffen School of Medicine at UCLA,Los Angeles,California.
Dana L Russell4Clinical Epidemiology and Infection Prevention,UCLA Health,Los Angeles,California.
David Elashoff3Department of Medicine Statistics Core,David Geffen School of Medicine at UCLA,Los Angeles,California.
Daniel Z Uslan1Division of Infectious Diseases,David Geffen School of Medicine at UCLA,Los Angeles,California.
University of California, Los Angeles · USUCLA Health · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881
6 · The paper itself

Abstract

OBJECTIVETo evaluate the impact of discontinuing routine contact precautions (CP) for endemic methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) on hospital adverse events.DESIGNRetrospective, nonrandomized, observational, quasi-experimental study.SETTINGAcademic medical center with single-occupancy rooms.PARTICIPANTSInpatients.METHODSWe compared hospital reportable adverse events 1 year before and 1 year after discontinuation of routine CP for endemic MRSA and VRE (preintervention and postintervention periods, respectively). Throughout the preintervention period, daily chlorhexidine gluconate bathing was expanded to nearly all inpatients. Chart reviews were performed to identify which patients and events were associated with CP for MRSA/VRE in the preintervention period as well as the patients that would have met prior criteria for MRSA/VRE CP but were not isolated in the postintervention period. Adverse events during the 2 periods were compared using segmented and mixed-effects Poisson regression models.RESULTSThere were 24,732 admissions in the preintervention period and 25,536 in the postintervention period. Noninfectious adverse events (ie, postoperative respiratory failure, hemorrhage/hematoma, thrombosis, wound dehiscence, pressure ulcers, and falls or trauma) decreased by 19% (12.3 to 10.0 per 1,000 admissions, P=.022) from the preintervention to the postintervention period. There was no significant difference in the rate of infectious adverse events after CP discontinuation (20.7 to 19.4 per 1,000 admissions, P=.33). Patients with MRSA/VRE showed the largest reduction in noninfectious adverse events after CP discontinuation, with a 72% reduction (21.4 to 6.08 per 1,000 MRSA/VRE admissions; P<.001).CONCLUSIONAfter discontinuing routine CP for endemic MRSA/VRE, the rate of noninfectious adverse events declined, especially in patients who no longer required isolation. This suggests that elimination of CP may substantially reduce noninfectious adverse events.Infect Control Hosp Epidemiol 2018;788-796.

Indexed as

Academic Medical CentersAdultAgedAnti-Infective Agents, LocalChlorhexidineCommunicable DiseasesCross InfectionDatabases, FactualFemaleGram-Positive Bacterial InfectionsHumansInfection ControlLos AngelesMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedAnti-Infective Agents, LocalChlorhexidinechlorhexidine gluconate

Identifiers

PMID29745356
PMCPMC6677236
OpenAlexW2801365574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.